Video

Role of First Generation FLT3 Inhibitors in AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.

Related Videos
Related Content
Visualization of bispecific antibody attacking cell | Image Credit: © miss irine - stock.adobe.com
May 29th 2025

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Diagnosed Multiple Myeloma

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Lymphoma cell | Image Credit: © Dr_Microbe - stock.adobe.com
May 29th 2025

Epcoritamab-bysp Yields Long-Term Disease Remission in Patients with Relapsed, Refractory Large B-Cell Lymphoma

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Red blood cells | Image Credit: © Anusorn - stock.adobe.com
May 27th 2025

Phase 3 Trial Explores Imetelstat for Advanced Myelofibrosis After Promising Phase 2 Data

Alexandra Gerlach, Associate Editor
Man holding kettlebell handle | Image Credit: © WIrul - stock.adobe.com
May 23rd 2025

Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma

Alexandra Gerlach, Associate Editor